MannKind’s Nintedanib DPI Shows Promise in IPF Phase 1b Trial
Event summary
- Phase 1b INFLO-1 trial met primary safety and tolerability objectives for nintedanib DPI in IPF patients.
- No serious adverse events, bronchospasm, or diarrhea reported; 90% of patients had no or mild cough.
- ~450 total inhalations administered across 27 patients with IPF at 10 U.S. sites.
- Global Phase 2 INFLO-2 trial actively enrolling 210 participants worldwide.
The big picture
MannKind’s positive Phase 1b results for nintedanib DPI in IPF patients validate its Technosphere® platform, offering a differentiated approach to pulmonary fibrosis treatment. The shift from oral to inhaled delivery aims to reduce systemic side effects, addressing an unmet need in a disease with limited therapeutic options. Success in later-stage trials could position MannKind as a key player in the IPF market.
What we're watching
- Clinical Validation
- Whether the Phase 2 INFLO-2 trial will confirm safety and efficacy signals observed in Phase 1b.
- Market Differentiation
- How MannKind’s Technosphere® platform compares to existing IPF treatments in terms of tolerability and lung delivery.
- Regulatory Pathway
- The pace at which MannKind advances nintedanib DPI through late-stage trials and potential FDA approval.